Beam Therapeutics inks deal with Pfizer worth up to $1.35B
Gene-editing firm Beam Therapeutics Inc. has signed a four-year deal worth up to $1.35 billion with pharmaceutical giant Pfizer Inc.
Pfizer (NYSE: PFE) is paying Cambridge-based Beam (Nasdaq: BEAM) $300 million up front to develop gene therapies for three targets for rare diseases in the liver, muscle and central nervous system. Milestone payments to Beam could reach up to $1.05 billion.
Pfizer will retain the options on exclu sive, global licenses for each development candidate; if it exercises…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Rowan Walrath Source Type: news
More News: Biotechnology | Gene Therapy | Genetics | Health Management | Liver | Pfizer | Rare Diseases | Urology & Nephrology